相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US
Sarah Shubeck et al.
JAMA NETWORK OPEN (2023)
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
Denise M. Wolf et al.
CANCER CELL (2022)
Characterizing Clinicopathologic Features of Estrogen Receptor-Positive/Progesterone Receptor-Negative Breast Cancers
Fei Fei et al.
CLINICAL BREAST CANCER (2022)
Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes
Naser Ansari-Pour et al.
NATURE COMMUNICATIONS (2021)
HER2+breast cancers evade anti-HER2 therapy via a switch in driver pathway
Alison E. Smith et al.
NATURE COMMUNICATIONS (2021)
Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden
Rong Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
Maria Vittoria Dieci et al.
NPJ BREAST CANCER (2021)
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns
Sarah M. Lima et al.
ECLINICALMEDICINE (2021)
Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients
Lihua Shang et al.
BREAST CANCER RESEARCH (2021)
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes
Fangyuan Zhao et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Shannon Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)
Kathriena Greenwell et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers
Kristen S. Purrington et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial
Douglas Yee et al.
JAMA ONCOLOGY (2020)
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
Claudia Omarini et al.
TRANSLATIONAL ONCOLOGY (2020)
FGF/FGFR signaling in health and disease
Yangli Xie et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Loss of HER2 after HER2-targeted treatment
Tanja Ignatov et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis
Jonathan Klein et al.
BMC CANCER (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Low Estrogen Receptor ( ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Is Response Similar to Typical ER-Positive or ER-Negative Disease?
Alessandra Landmann et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey et al.
CELL (2018)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features
Jason J. Pitt et al.
NATURE COMMUNICATIONS (2018)
Frequency of breast cancer subtypes among African American women in the AMBER consortium
Emma H. Allott et al.
BREAST CANCER RESEARCH (2018)
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas
Dezheng Huo et al.
JAMA ONCOLOGY (2017)
Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Marie Klintman et al.
CLINICAL CANCER RESEARCH (2016)
Time to Surgery and Breast Cancer Survival in the United States
Richard J. Bleicher et al.
JAMA ONCOLOGY (2016)
Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer
Mariana Chavez-MacGregor et al.
JAMA ONCOLOGY (2016)
Race, response to chemotherapy, and outcome within clinical breast cancer subtypes
J. R. Tichy et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Brigid K. Killelea et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Katarzyna Tomczak et al.
Wspolczesna Onkologia-Contemporary Oncology (2015)
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
E. H. Lips et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
Nehmat Houssami et al.
EUROPEAN JOURNAL OF CANCER (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Pathologic Complete Response in Breast Cancer Patients Receiving Anthracycline- and Taxane-Based Neoadjuvant Chemotherapy Evaluating the Effect of Race/Ethnicity
Mariana Chavez-MacGregor et al.
CANCER (2010)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2009)
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies
Erik von Elm et al.
ANNALS OF INTERNAL MEDICINE (2007)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
分享论文
